

Bioclanic 250 mg + 62.5 mg flavoured tablets for cats and dogs

Authorised

- Amoxicillin
- Clavulanic acid

Product identification

Medicine name:

Bioclanic 250 mg + 62.5 mg flavoured tablets for cats and dogs

Active substance:

Amoxicillin

Clavulanic acid

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin

250.00 milligram(s) / 1.00 Tablet

Clavulanic acid

62.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CR02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Available in:

Ireland

Package description:

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 10 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 20 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 30 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 40 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 50 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 100 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 150 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 200 tablets.

oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes: cardboard box of 250 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

Marketing authorisation holder:

Axience

Marketing authorisation date:

26/07/2024

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA22873/005/002

Date of authorisation status change:

26/07/2024

Reference member state:

Ireland

Procedure number:

IE/V/0788/002

Concerned member states:

Austria Belgium Cyprus Greece Hungary Italy Netherlands Poland Portugal
Romania Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics